GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Toleranzia AB (OSTO:TOL) » Definitions » Current Deferred Revenue

Toleranzia AB (OSTO:TOL) Current Deferred Revenue : kr0.00 Mil (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Toleranzia AB Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Toleranzia AB's current deferred revenue for the quarter that ended in Mar. 2025 was kr0.00 Mil.

Toleranzia AB Current Deferred Revenue Historical Data

The historical data trend for Toleranzia AB's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Toleranzia AB Current Deferred Revenue Chart

Toleranzia AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Toleranzia AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Toleranzia AB Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Toleranzia AB's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Toleranzia AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Toleranzia AB (OSTO:TOL) » Definitions » Current Deferred Revenue
Comparable Companies
OSTO:VIVE OSTO:KLAR OSTO:ERMA OSTO:NEWBRY XSAT:ACUC XSAT:ODI XSAT:PMED OSTO:GABA XSAT:DANCAN OSTO:NANEXA ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA
Traded in Other Exchanges
N/A
Address
Arvid Wallgrens backe 20, 8th floor, Gothenburg, SWE, 413 46
Website
https://www.toleranzia.com
Toleranzia AB is a Swedish biotechnology company. It develops drugs that harness the power of the immune system to treat autoimmune orphan diseases. The company uses its tolerance technology for drug development, which is based on the identification of disease-specific proteins that are developed into biological drugs, specific to each autoimmune disease. Its drug development pipeline includes TOL2, which is being developed for the treatment of autoimmune orphan disease myasthenia gravis, and TOL3, being developed for another indication in autoimmune orphan diseases, ANCA vasculitis.